Russia is a large market for pharmaceuticals, and has a
population of more than 140 million, developed retail chains and a
large state procurement system. Since the market is big and
competition tough, effective patent protection provides invaluable
tools for safeguarding the market position.
Moreover, the knowledge of key trends in the Russian legal
landscape in terms of pharma patent litigation, intellectual
property and regulatory issues, and approaches in interpreting the
correlation between the IP aspects of competition regulations, may
help to better understand the market situation from the legal
prospective.
Litigation
Effective on June 1, 2016, important procedural amendments
(obligatory complaint procedures) will come into force in terms of
strategy that will affect pharma patent litigation. Currently
patentees are not obliged to send cease-and-desist letters to
potential defendants (manufacturers, distributors, importers of
patent-infringing generic
